Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Isentress sales will further decline once dolutegravir is available and patients will switch as the latter has a better profile.
Probably true in many cases, but I was thinking of the fact that animal generic drugs have to be tested in every species they can be used for and that's a big hurdle.
PKI posts another solid quarter in 4Q12. Reported $0.65 non-GAAP EPS for the quarter, right in the middle of guidance.
http://www.i3investor.com/servlets/fdnews/115825.jsp
Anti-PD1 drugs
One more positive point is that there might be a predictive marker - PD-L1 expression in tumors.
TEVA dumps CureTech's anti-PD1
http://www.globes.co.il/serveen/globes/docview.asp?did=1000818643&fid=1725
I don't know but I think it depends on price, number of patients (with rare life-threatening diseases I'm certain insurers are reluctant to intervene), and profile of the generic vs the brand.
Time will tell and until Viread goes generic, which pill do you think will sell better Stribild or Complera?
Yes, of course I meant a single pill containing 3 generic drugs (Viread, Sustiva, and another generic NRTI).
I think that after Viread goes generic, payors can push to use in first line a one-pill-all-generic regimen of generic Sustiva and another generic NRTI and this will make life harder for branded regimens that are not superior.
GILDās āQuad Primeā advances to phase-3
I have posted once on Roy's board about this interesting little com. #msg-64676775 and it did very well since.
FDA rejected but CHMP gave positive opinion for Ilaris in gouty arthritis
http://www.novartis.com/newsroom/media-releases/en/2013/1671412.shtml
LIFE now up premarket on this:
" The board of directors of Life Technologies Corporation has retained Deutsche Bank Securities Inc. and Moelis & Company LLC to assist in its annual strategic review."
http://finance.yahoo.com/news/statement-life-technologies-board-directors-074500735.html
CANFY
Dubi, If you wanna translate for ghmm :)
http://www.sponser.co.il/Article.aspx?ArticleId=29476
Try this (sorry, there was a comma in the previous link)
http://www.parkinsontrial.ninds.nih.gov/pdf/neurology032006-66-664-671.pdf
Didn't mean a single arm trial. Was talking about a randomized, double-blind, futility clinical trial like this one in Parkinson's: http://www.parkinsontrial.ninds.nih.gov/pdf/neurology032006-66-664-671.pdf, where the threshold for futility was obtained from historical data.
Thanks, Clark. BAX noted that in general:
BAX/IVIG Alzheimer's
This phase III trial of Gammagard is in mild-to-moderate Alzheimer's (http://clinicaltrials.gov/ct2/show/NCT00818662?term=Gammagard++alzheimer&phase=2&rank=2 ), which now we know is too late (better shot with the mild subgroup but will be too small), so low chance to be able to show impact on disease progression (cognitive and functional). The trial was not stopped for futility, so it probably has at least 20% chance of success.
ProCognia
New owners, new management, same science, still mainly a service provider. So still not a direct competitor to MNTA.
GIVN
I was right about Humi:
http://maya.tase.co.il/bursa/report.asp?report_cd=790152-00&CompCd=2200&Type=Pdf
You can compare the language used by the FDA:
Brainsway's device is approved for the treatment of Major Depressive Disorder in patients who have failed to respond to antidepressant medications in their current episode of depression.
Neuronetics' device is approved for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.
Antidepressants are 1st line and a patient can try one of the TMS treatments before ECT.
Brainsway's depression treatment device is the second FDA approved TMS device for treating depression. Neuronetics has its device in the market since Oct. 08 #msg-34025303. Wonder how are they doing.
MRK knows that the drug will most likely be suspended by the EMA next week.
I need a lesson on baseball to understand your analogy
My money is on GILD even if it is not first to market.
GILD reports SVR4 for sofosbuvir+GS-5885+ribavirin in null responders and more updates:
http://finance.yahoo.com/news/gilead-provides-hepatitis-c-development-133000022.html